Growth & profitability
- Revenue has grown 0.0% per year over the past 5 years.
Financial health
- Total debt has grown slower than revenue (-10.8% vs 0.0% per year).
IMNN Financials Imunon, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | $14M | — | — | -$14M | — | $9M |
| 2024 | — | -$19M | — | — | -$19M | — | $6M |
| 2023 | — | -$20M | — | — | -$19M | — | $6M |
| 2022 | $500000 | -$36M | 0.0% | -4984.3% | -$23M | $6M | $11M |
| 2021 | $500000 | -$21M | 0.0% | -4201.4% | -$17M | — | $20M |
| 2020 | $500000 | -$21M | 0.0% | -3697.3% | -$16M | $5M | $17M |
| 2019 | $500000 | -$17M | 0.0% | -4113.1% | -$21M | $10M | $7M |
| 2018 | $500000 | -$12M | 0.0% | -4213.0% | -$7M | $9M | $13M |
| 2017 | $500000 | -$20M | 0.0% | -3693.7% | -$17M | — | $11M |
| 2016 | — | -$22M | — | — | -$18M | — | $3M |
| 2015 | — | -$22M | — | — | -$21M | — | $9M |
| 2014 | — | -$25M | — | — | -$22M | — | $13M |
| 2013 | — | -$8M | — | — | -$10M | $5M | $6M |
| 2012 | — | -$27M | — | — | -$23M | $5M | $15M |
| 2011 | — | -$23M | — | — | -$23M | — | $20M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$4M | — | — | — | — | $5M |
| Dec '25 | — | -$4M | — | — | -$4M | — | $9M |
| Sep '25 | — | -$3M | — | — | -$4M | — | $5M |
| Jun '25 | — | -$3M | — | — | -$3M | — | $5M |
| Mar '25 | — | -$4M | — | — | -$3M | — | $3M |
| Dec '24 | — | -$4M | — | — | -$4M | — | $6M |
| Sep '24 | — | -$5M | — | — | -$4M | — | $10M |
| Jun '24 | — | -$5M | — | — | -$5M | — | $5M |
| Mar '24 | — | -$5M | — | — | -$6M | — | $2M |
| Dec '23 | — | -$5M | — | — | -$4M | — | $6M |
| Sep '23 | — | -$3M | — | — | -$5M | — | $13M |
| Jun '23 | — | -$6M | — | — | -$7M | — | $7M |
| Mar '23 | — | -$6M | — | — | -$4M | $6M | $10M |
| Dec '22 | $125000 | -$13M | 0.0% | -5541.4% | -$5M | $6M | $11M |
| Sep '22 | $125000 | -$6M | 0.0% | -4939.7% | -$5M | $6M | $27M |
| Jun '22 | $125000 | -$6M | 0.0% | -4782.6% | -$6M | $6M | $27M |
| Mar '22 | $125000 | -$10M | 0.0% | -4673.6% | -$8M | $6M | $28M |
| Dec '21 | $125000 | -$4M | 0.0% | -4392.7% | -$5M | — | $20M |
| Sep '21 | $125000 | -$5M | 0.0% | -4049.3% | -$4M | $6M | $26M |
| Jun '21 | $125000 | -$5M | 0.0% | -4057.1% | -$3M | $6M | $26M |
Valuation over time
How the market has priced IMNN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 10.4× (Mar '23) to 5.9× (Dec '23).
P/E
P/S
Frequently asked questions
Is IMNN growing its revenue and profit?
Over the past 5 years, Imunon, Inc.'s revenue has grown 0.0% per year. These are computed facts, not advice.
How much debt does IMNN have?
As of FY2025, Imunon, Inc. reported — of total debt against $9M of cash.
What is IMNN's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is IMNN's P/E ratio?
As of Jun '26, Imunon, Inc. traded at a price-to-earnings ratio of about 1.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.